Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
OTLK Stock Chart & Stats
$0.44
-$0.17(-7.61%)
At close: 4:00 PM EST
$0.44
-$0.17(-7.61%)
Day’s Range― - ―
52-Week Range$0.38 - $3.39
Previous CloseN/A
Volume358.39K
Average Volume (3M)7.51M
Market Cap
$32.42M
Enterprise Value$247.71B
Total Cash (Recent Filing)$8.08M
Total Debt (Recent Filing)$247.70B
Price to Earnings (P/E)―
Beta0.82
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding73,509,450
10 Day Avg. Volume1,555,117
30 Day Avg. Volume7,507,910
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00003
P/FCF Ratio>-0.01
Enterprise Value/Market Cap7.64K
Enterprise Value/Revenue175.24K
Enterprise Value/Gross Profit-354.89M
Enterprise Value/Ebitda-3.61K
Forecast
1Y Price Target
$3.83Price Target Upside770.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst Valuation UpdateAnalyst maintains a buy rating and raises the twelve-month price target to ten dollars based on a net present value analysis, indicating material upside from the current share price.
Clinical Trial EfficacyONS-5010 achieved noninferiority to ranibizumab in the NORSE EIGHT study at week twelve, supporting the drug's therapeutic competitiveness.
European Commercial LaunchLaunch of LYTENAVA in the U.K. and Germany is progressing and could reach breakeven in 2026, demonstrating early commercialization potential in Europe.
Bears Say
Financing And Commercial RunwayVery limited cash on hand implies external funding would be required to support additional clinical studies or build commercial operations, increasing dilution and operational risk.
Market Pricing PressureSharp price declines for ranibizumab and expansion of biosimilars have reduced the addressable commercial opportunity for ONS-5010, constraining revenue potential if approved.
Regulatory UncertaintyFDA issuance of a complete response letter for ONS-5010 cited insufficient evidence of effectiveness and did not specify acceptable confirmatory evidence, leaving the approval pathway unclear.
Outlook Therapeutics News
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.38 and its highest was $3.39 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $32.42M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is May 14, 2026 which is in 88 days.
How were Outlook Therapeutics’s earnings last quarter?
Currently, no data Available
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 73,509,450 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outlook Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.83 (770.45% Upside)
$3.83 (770.45% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 151.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Bearish
Bullish news 39%
Bearish news 67%
Bearish news 67%
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
OTLK Stock 12 Month Forecast
Average Price Target
$3.83
▲(770.45% Upside)
Technical Analysis
Ownership Overview
22.01% Insiders
2.28% Mutual Funds
<0.01% Other Institutional Investors
73.65% Public Companies and Individual Investors